DelveInsight’s “Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Metastatic Colorectal Cancer market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Metastatic Colorectal Cancer drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Metastatic Colorectal Cancer treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Metastatic Colorectal Cancer: An Overview
Colorectal Cancer (CRC) is the third most common type of cancer, with metastasis being the major cause of death in the majority of patients. Colorectal Cancer that spreads, or metastasizes, to the lungs, liver or any other organ is called metastatic colorectal cancer (mCRC).
Colorectal Cancer usually begins as a polyp that develops in the inner lining of the rectum or colon and grows and converts slowly over several years. Once the cancer develops, it can grow further into the wall of the colon or rectum and go on to invade blood or lymph vessels.
Generally, most Colorectal Cancer (95%) are considered sporadic, meaning the genetic changes develop by chance after a person is born, so there is no risk of passing these genetic changes on to one’s children. Inherited Colorectal Cancer are less common (5%) and occur when gene mutations, or changes, are passed within a family from one generation to the next. Often, the cause of Colorectal Cancer is not known.
The major sites of tumor localization in Colorectal Cancer are right colon, transverse, left colon, rectosigmoid and rectum. After someone is diagnosed with Colorectal Cancer, staging is done to figure out if it has spread, and if so, how far. Colorectal Cancer can be divided into localized, regional, distant and unknown based on Colorectal Cancer staging.
The market space of mCRC would benefit in the coming years with the launch of several emerging therapies. These therapies include triplet combination of Braftovi + Mektovi + Erbitux, Modufolin (arfolitixorin) + bevacizumab, Adagrasib, Lumakras (sotorasib) + panitumumab, Elunate (fruquintinib), Tukysa (tucatinib) ± Herceptin (trastuzumab), Onvansertib.
Metastatic Colorectal Cancer Market Key Facts
-
The total market size of Metastatic Colorectal Cancer in the United States accounted for USD 5,155.1 million in 2021.
-
In EU5, the total market size of Metastatic Colorectal Cancer was USD 4,618.5 million in 2021.
-
In Japan, the total market size of Metastatic Colorectal Cancer was USD 2,840.4 million in 2021.
-
In the year 2021, the total incident cases of Metastatic Colorectal Cancer were 241,115 cases in the 7MM.
-
Globally, CRC is the third most commonly diagnosed cancer in males and the second in females, with 1.8 million new cases and almost 861,000 deaths in 2018, according to the World Health Organization GLOBOCAN database.
-
In the year 2021, the total incident cases of Colorectal Cancer were around 539,240 cases in the 7MM, which might increase by 2032.
-
In the 7MM, the highest number of incident cases of Colorectal Cancer was observed in the US, with approximately 148,940 cases in the year 2021.
-
In the year 2021, the total incident cases of metastatic colorectal cancer were around 241,120 cases in the 7MM.
-
In the EU-5 countries, the incident cases of metastatic colorectal cancer were around 108,220 cases in the year 2021, with the highest cases being reported in Germany.
Metastatic Colorectal Cancer Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Metastatic Colorectal Cancer pipeline therapies. It also thoroughly assesses the Metastatic Colorectal Cancer market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Metastatic Colorectal Cancer drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Metastatic Colorectal Cancer Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Metastatic Colorectal Cancer epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Metastatic Colorectal Cancer epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Metastatic Colorectal Cancer Epidemiology, Segmented as –
-
Incident Cases of Colorectal Cancer (CRC) in the 7MM [2019-2032]
-
Incident Cases of Metastatic Colorectal Cancer (mCRC) in the 7MM [2019-2032]
Metastatic Colorectal Cancer Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Metastatic Colorectal Cancer market or expected to be launched during the study period. The analysis covers the Metastatic Colorectal Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Metastatic Colorectal Cancer drugs based on their sale and market share.
The report also covers the Metastatic Colorectal Cancer pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Metastatic Colorectal Cancer companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Metastatic Colorectal Cancer Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
Metastatic Colorectal Cancer Therapeutics Analysis
The treatment plan for mCRC may include a combination of surgery, radiation therapy, immunotherapy, and chemotherapy, which can be used to slow the spread of the disease and often temporarily shrink a cancerous tumor. Palliative care is also important to help relieve symptoms and side effects.
The first, second, and third-line treatment regimen of mCRC involves the use of multi-agent chemotherapy (i.e. Folfox, Folfiri, Capeox), anti-angiogenesis therapy with or without chemotherapy, epidermal growth factor receptor (EGFR) inhibitors with or without chemotherapy, and others with or without chemotherapy. Along with these therapies, Opdivo, with or without Yervoy, and Braftovi, in combination with Erbitux, are approved for the treatment of mCRC patients as the only second and third-line therapies, while Keytruda is approved as the only first-line therapy of mCRC.
Metastatic Colorectal Cancer Companies Actively Working in the Therapeutics Market Include
Merck, Alexion Pharmaceuticals, GlaxoSmithKline (GSK), Array BioPharma/ Pfizer + Pfizer, Eli Lilly, Taiho Oncology, Bristol-Myers Squibb, Amgen, Mirati Therapeutics + Merck, Hutchison Medipharma, G1 Therapeutics, Amgen, AB Science, Incyte Corporation, Daiichi Sankyo/AstraZeneca, Merck/Janssen, Cardiff oncology, EpicentRx, Merck/Eisai, Seagen + Roche, NeoImmuneTech (Genexine) + Merck, Black Diamond Therapeutics, Gilead Sciences + Eli Lilly and Company, Ludwig Institute for Cancer Research + Targovax ASA, and others.
Emerging and Marketed Metastatic Colorectal Cancer Therapies Covered in the Report Include:
-
Keytruda (pembrolizumab) injection: Merck
-
Stivarga (Regorafenib): Alexion Pharmaceuticals
-
Jemperli (dostarlimab): GlaxoSmithKline (GSK)
-
Braftovi (encorafenib) + Erbitux (cetuximab) ± Mektovi (binimetinib): Array BioPharma/ Pfizer + Pfizer
-
Adagrasib (MRTX849) + cetuximab: Mirati Therapeutics + Merck
-
MK-4280A (favezelimab and pembrolizumab): Merck
-
Elunate (fruquintinib/HMPL-013): Hutchison Medipharma
-
Corsela (trilaciclib): G1 Therapeutics
-
Modufolin (arfolitixorin): Isofol Medical
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Metastatic Colorectal Cancer Competitive Intelligence Analysis
4. Metastatic Colorectal Cancer Market Overview at a Glance
5. Metastatic Colorectal Cancer Disease Background and Overview
6. Metastatic Colorectal Cancer Patient Journey
7. Metastatic Colorectal Cancer Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Metastatic Colorectal Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Metastatic Colorectal Cancer Unmet Needs
10. Key Endpoints of Metastatic Colorectal Cancer Treatment
11. Metastatic Colorectal Cancer Marketed Therapies
12. Metastatic Colorectal Cancer Emerging Drugs and Latest Therapeutic Advances
13. Metastatic Colorectal Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Metastatic Colorectal Cancer Market Outlook (In US, EU5, and Japan)
16. Metastatic Colorectal Cancer Companies Active in the Market
17. Metastatic Colorectal Cancer Access and Reimbursement Overview
18. KOL Views on the Metastatic Colorectal Cancer Market
19. Metastatic Colorectal Cancer Market Drivers
20. Metastatic Colorectal Cancer Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/metastatic-colorectal-cancer-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
mRNA Vaccine and Therapeutics Market
“mRNA Vaccine and Therapeutics Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted mRNA Vaccine and Therapeutics market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the mRNA Vaccine and Therapeutics market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research